PolyTechnos Venture Partners
VC Fund
Munich, Germany
PolyTechnos Venture Partners is a VC fund in Munich focused on Manufacturing and Health Care. PolyTechnos Venture-Partners is an independent European venture capital firm headquartered in Munich, with locations in Dublin, New York and San Francisco with a track record of building world class technology companies. PolyTechnos Venture-Partners nurtures technological innovation and guides exceptional entrepreneurs in growing world classbusinesses for the benefit of its advised funds' investors and society. Entrepreneurial teams with pioneering technologies and promising business models require more than just capital for long term success. PolyTechnos Venture-Partners help companies turn technology into business by providing support in areas such as strategy, business development, and organization building. The investment team combines long standing venture capital investment experience with broad international operational and management expertise based on strong technology and life science backgrounds.
- Total investments:
- 16
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries PolyTechnos Venture Partners invests in
Stages PolyTechnos Venture Partners invests in
Countries PolyTechnos Venture Partners invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Eric Achtmann
|
|||
Knut Heitmann
|
|||
Tonio Barlage
|
|||
Wolfgang Oster
|
|||
1 more contact available
Investment Focus
Industry
- Manufacturing 4 (25%)
- Health Care 3 (19%)
- Biotechnology 3 (19%)
- Pharmaceutical 3 (19%)
- Semiconductor 2 (13%)
Stage
- Series B 5 (31%)
- Series C 4 (25%)
- Series A 2 (13%)
- Funding Round 2 (13%)
- Series D 1 (6%)
Country
- Germany 4 (25%)
- Switzerland 2 (13%)
- Israel 1 (6%)
- Ireland 1 (6%)
- United States 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Eric Achtmann
Partner
|
Partner | Total investments: 0 | Find email | |
|
Knut Heitmann
Founding Partner
|
Founding Partner | Total investments: 0 | Find email | |
|
Tonio Barlage
Partner
|
Partner | Total investments: 0 | Find email | |
|
Wolfgang Oster
Partner
|
Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
ColorChip
|
ColorChip designs and manufactures optical sub-systems and components for the Datacom and Telecom markets. These sub-systems and components are based on Application Specific Photonic Integrated Circuits (ASPICs) that leverage the company's unique and robust PLC technology. | $3.8M / Oct 31, 2013 | |
Cappella Medical Devices
|
Cappella, Inc., a Dover, Del.- and Galway, Ireland-based medical device company that is developing novel solutions for the treatment of Complex Coronary Artery Disease (CAD) and specifically bifurcation vascular disease.The company was founded in 2004 by Antonio Columbo, M.D., Chief of Invasive Cardiology at San Raffaele Hospital in Milan,Italy, and Ascher Shmulewitz, M.D., Ph.D., a cardiologist, medical device entrepreneur and founder of NeoVision, Xcardia and Labcoat Ltd., and established its European headquarters in Galway in 2005. | $11.5M / Series D / Oct 28, 2010 | |
|
Cappella Medical Devices
|
Cappella, Inc., a Dover, Del.- and Galway, Ireland-based medical device company that is developing novel solutions for the treatment of Complex Coronary Artery Disease (CAD) and specifically bifurcation vascular disease.The company was founded in 2004 by Antonio Columbo, M.D., Chief of Invasive Cardiology at San Raffaele Hospital in Milan,Italy, and Ascher Shmulewitz, M.D., Ph.D., a cardiologist, medical device entrepreneur and founder of NeoVision, Xcardia and Labcoat Ltd., and established its European headquarters in Galway in 2005. | $17.3M / Series C / Jul 22, 2009 | |
BiPar Sciences
|
BiPar Sciences Inc. is a Brisbane, CA based developer of PARP inhibitors as cancer therapies. BiPar's key experimental product is BSI-201, currently in mid-stage trials for advanced breast cancer, ovarian cancer and other tumors.BiPar has raised around $60 million in VC funding, from firms like On April 15th, 2009, French drug maker | $20M / Series C / Jan 12, 2009 | |
Nanotron Technologies
|
Nanotron Technologies is a leader in the development of wireless products that combine high speed data transmission and location information at about 1 meter accuracy. Their wireless technology guarantees high signal robustness and low energy consumption. Nanotron's key product nanoLOC delivers both wireless communication and location inone solution. The wireless industry has many technologies for wireless communication and has some solutions for location, but only nanoLOC delivers both in one chip. | $17.4M / Jun 23, 2008 | |
NemeriX
|
NemeriX SA operates as a fabless semiconductor company that develops ultra-low-power, semiconductors, and software solutions for global positioning system and location-based service products. Its products include analog RF receivers, baseband, and indoor global positioning system integrates chips, as well as global positioning systems basedintegrated chipset. The company also offers OS support for WinCE, WinMobile, WinXP, LinuX, Symbian, and Nucleus; NeX, an extended ephemeris solution that enables mobile devices to acquire immediate positioning information in difficult garage scenarios and in harshest multi-path environments; SUPL client, which is inter-operated with several independent SUPL servers. In addition, it offers solutions to enable product integration, including evaluation boards, system software reference designs, user documentation, online support, and access to designers and global cadre of application engineers. The company’s product application areas include cellular phones, battery-powered wireless and handheld terminals, personal navigation devices, personal media players, and digital still cameras. It serves proximity-based marketing, social networking, gaming and financial authentication, navigation, tracking, and emergency markets. The company was founded in 2002 and is based in Manno, Switzerland. It has a design center in Cambridge, the United Kingdom; an applications center in Seoul, Korea; a technical center in Taipei, Taiwan; and sales offices in the United States, Europe, Taiwan, and Japan. | $22.7M / Series C / Sep 17, 2007 | |
|
Nanotron Technologies
|
Nanotron Technologies is a leader in the development of wireless products that combine high speed data transmission and location information at about 1 meter accuracy. Their wireless technology guarantees high signal robustness and low energy consumption. Nanotron's key product nanoLOC delivers both wireless communication and location inone solution. The wireless industry has many technologies for wireless communication and has some solutions for location, but only nanoLOC delivers both in one chip. | $10.3M / Jul 09, 2007 | |
|
BiPar Sciences
|
BiPar Sciences Inc. is a Brisbane, CA based developer of PARP inhibitors as cancer therapies. BiPar's key experimental product is BSI-201, currently in mid-stage trials for advanced breast cancer, ovarian cancer and other tumors.BiPar has raised around $60 million in VC funding, from firms like On April 15th, 2009, French drug maker | $35M / Series B / Feb 26, 2007 | |
|
ColorChip
|
ColorChip designs and manufactures optical sub-systems and components for the Datacom and Telecom markets. These sub-systems and components are based on Application Specific Photonic Integrated Circuits (ASPICs) that leverage the company's unique and robust PLC technology. | $7.5M / Series C / Feb 20, 2007 | |
Addex Therapeutics
|
Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and mayoffer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is in a pivotal registration clinical trial for Parkinson’s disease levodopa induced dyskinesia (PD-LID). Addex is also investigating dipraglurant's therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in Q3 2021. Addex's third clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc., is in a Phase 2a proof of concept clinical trial for the treatment of epilepsy. Indivior PLC has licensed Addex’s GABAB PAM program for the development of drug candidates with a focus in addiction. Preclinical programs ongoing with Addex include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders. | $29.4M / Series C / Sep 19, 2006 | |
| See all 16 investments → | |||
Co-Investors
Asset Management Company
3 deals together
Asset Management Ventures (AMV)
3 deals together
Canaan Partners
3 deals together
IBB Ventures
3 deals together
Quantum Technology Partners
3 deals together
Vulcan Capital
3 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does PolyTechnos Venture Partners invest in?
PolyTechnos Venture Partners invests primarily in Manufacturing, Health Care and Biotechnology startups, most often at Series B and Series C stage. Most of the 16 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact PolyTechnos Venture Partners?
Public channels for PolyTechnos Venture Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at PolyTechnos Venture Partners?
The team at PolyTechnos Venture Partners includes Eric Achtmann (Partner), Knut Heitmann (Founding Partner) and Tonio Barlage (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
